Recent Updates
Recently added Catalysts
RARE Negative Sentiment Score: 25/100

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Key Takeaway: Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for failing to disclose crucial information during a specified class period. This follows the company's announcement that its Phase 3 studies for setrusumab did not yield statistically significant results for treating osteogenesis imperfecta, leading to a near 42% drop in share price. Investors who incurred losses exceeding $100,000 have until April 6, 2026, to file lead plaintiff applications in this ongoing case. The lawsuit is being pursued in the United States District Court for the Southern District of New York.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ultragenyx faced a significant decline in share price after clinical trial results were announced.
  • The Phase 3 studies for setrusumab failed to demonstrate meaningful efficacy for osteogenesis imperfecta.
  • The company is planning to implement significant expense reductions due to the trial failures.
  • Investors are now reminded of a class action lawsuit due to alleged failure to disclose material information.

Full Press Release Details

NEW ORLEANS, March 11, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Ultragenyx investors should visit us at https://claimsfiler.com/cases/nasdaq-rare/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Ultragenyx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.” On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.
The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline for filing lead plaintiff applications?

Investors must file lead plaintiff applications by April 6, 2026.

What is the duration of the Ultragenyx class period?

The class period for Ultragenyx spans from August 3, 2023, to December 26, 2025.

What caused Ultragenyx's share price to drop?

The share price fell due to failed Phase 3 study results for setrusumab.

Who can investors contact for legal advice?

Investors can contact Kahn Swick & Foti, LLC for legal options.

How can investors learn more about ClaimsFiler?

Visit www.claimsfiler.com for more information about their services.

Last updated: Mar 12, 2026